About Biopharma Credit (LON:BPCR)
BioPharma Credit Plc is a closed-ended investment company. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company may acquire debt assets from a company operating in the life sciences industry or an entity other than a life sciences company, which directly or indirectly holds an interest in royalty rights to certain products, including any investment vehicle or special purpose vehicle. The Company's un-invested capital may be invested in cash instruments or bank deposits for cash management purposes. The Company may, from time to time, enter into such hedging or other derivative arrangements. The Company's investment manager is Pharmakon Advisors L.P.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on Equity5.84%
Return on Assets5.81%
Biopharma Credit (LON:BPCR) Frequently Asked Questions
What is Biopharma Credit's stock symbol?
Biopharma Credit trades on the London Stock Exchange (LON) under the ticker symbol "BPCR."
How often does Biopharma Credit pay dividends? What is the dividend yield for Biopharma Credit?
Biopharma Credit announced a dividend on Thursday, March 1st. Investors of record on Thursday, March 8th will be given a dividend of GBX 0.02 per share on Thursday, March 29th. This represents a yield of 2.04%. The ex-dividend date is Thursday, March 8th. This is a positive change from Biopharma Credit's previous dividend of $0.01. The official announcement can be accessed at this link. View Biopharma Credit's Dividend History.
Who are Biopharma Credit's key executives?
Biopharma Credit's management team includes the folowing people:
- Jeremy W. Sillem, Chairman of the Board
- Colin Bond, Director (Age 56)
- Duncan W. A. Budge, Director (Age 61)
- Harry Abraham Hyman, Director
Has Biopharma Credit been receiving favorable news coverage?
Media coverage about BPCR stock has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Biopharma Credit earned a media sentiment score of 0.24 on Accern's scale. They also assigned media coverage about the company an impact score of 45.04 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Biopharma Credit?
Shares of BPCR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Biopharma Credit's stock price today?
One share of BPCR stock can currently be purchased for approximately GBX 1.03.
How big of a company is Biopharma Credit?
Biopharma Credit has a market capitalization of £937.11 million.
MarketBeat Community Rating for Biopharma Credit (BPCR)MarketBeat's community ratings are surveys of what our community members think about Biopharma Credit and other stocks. Vote "Outperform" if you believe BPCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biopharma Credit (LON:BPCR) Analyst Ratings History
(Data available from 4/24/2016 forward)
Biopharma Credit (LON:BPCR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Biopharma Credit (LON BPCR) Insider Trading and Institutional Ownership History
Biopharma Credit (LON BPCR) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/28/2017||Harry Abraham Hyman||Insider||Buy||2,000||GBX 82||£1,640|
Biopharma Credit (LON BPCR) News Headlines
Biopharma Credit (LON:BPCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Biopharma Credit (LON BPCR) Stock Chart for Tuesday, April, 24, 2018